

NCI Grant of \$150k

First-of-a-kind diagnostic tool is quick, non-invasive and inexpensive.

DENVER (October 16, 2007): The National Cancer Institute (NCI) has awarded a \$150,000 contract to ADA Technologies to research and develop a low-cost antibody array system for early detection and diagnosis of breast cancer.

ADA will develop a highly sensitive and specific, low-cost cancer diagnostic kit that can be used by clinical laboratories to perform rapid quantitative analysis of multiple cancer biomarkers. Biomarkers are specific proteins detected in higher-than-normal amounts in the blood, saliva or urine of patients with certain types of cancer.

The core technology of ADA's cancer diagnostic kit is a disposable biochip, which combines recent advances in protein microarray platform technology, nanotechnology, surface chemistry, electrical engineering and cancer proteomics (the study of the functions and interactions of cancer-related proteins).

"Although the NCI project focuses specifically on analyzing six biomarkers related to breast cancer, this research is important to the early detection of numerous types of cancer," said Clifton H. Brown, Jr., ADA president and CEO. "Because this technology is quick, non-invasive and inexpensive, it will be extremely useful for enhancing health care delivery in the community setting and in underserved populations."

Recent developments in gene and proteomic profiling of precancerous and cancerous tissue suggest that a combination or a pattern of biomarkers may be used to distinguish between cancer and non-cancer cells with high sensitivity and specificity, reducing the incidence of false positive and false negative results. Currently, there is nothing available that meets the requirements for clinical detection of cancer biomarkers.

"Early detection is critical in cancer control and prevention," said Xichun Zhou, Ph.D., ADA senior scientist and the project's principal investigator. "But the non-invasive, inexpensive diagnostic tools needed for widespread applicability have not been available. ADA's cancer diagnostic kit will make it possible and affordable to detect cancer biomarkers, allowing for early diagnosis and treatment of many forms of cancer."

ADA's cancer diagnostic kits are expected to be undergoing clinical trials within two years.

About ADA Technologies, Inc.

ADA Technologies, Inc. is a research, development, and commercialization company that specializes in creating and converting innovative technologies to commercial successes. The firm is headquartered in Littleton, Colorado, with an office on the University of Wyoming campus in Laramie. ADA has received more than 130 research grants totaling more than \$40 million and holds numerous patents for its technologies, which focus on solving problems threatening the health, security, environment and quality of life worldwide. ADA has received numerous honors, including: 2006 Tibbetts Award, Colorado Technology Fast 50 (2007, 2006), Best Companies to Work For in Colorado (2007, 2006), and Colorado's Top Technology Company 2005. For more information, please visit www.adatech.com or call 303-792-5615.

National Institutes of Health

This project is 100 percent funded with Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN261200700035C.



Technologies, Inc.

###

Taking Today's Technologies into Tomorrow's Markets
